CD4 and neoplasm: Indeed, several studies using genomic and bioinformatics approaches to design personalized neoantigen vaccines report a strong neoantigen-specific anti-tumor CD4+ and CD8+ T cell response correlated with tumor control in mice and humans [21,22,23,24,25].